Filter

Refine by date

—

Refine by collections

  • Print
  • Save

Search Results

You are looking at 1 - 10 of 12 items for :

  • "larotrectinib" x
Clear All
Abdul Rehman Syed University of Calgary, Calgary, Alberta, Canada

Search for other papers by Abdul Rehman Syed in
Google Scholar
PubMed Close
,
Aakash Gorana Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Alberta, Canada

Search for other papers by Aakash Gorana in
Google Scholar
PubMed Close
,
Erik Nohr Alberta Precision Laboratories, Molecular Pathology Program, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada

Search for other papers by Erik Nohr in
Google Scholar
PubMed Close
,
Xiaoli-Kat Yuan Precision Oncology Hub Laboratory, Tom Baker Cancer Centre, Calgary, Alberta, Canada

Search for other papers by Xiaoli-Kat Yuan in
Google Scholar
PubMed Close
,
Parthiv Amin MASc Department of Radiology, Cumming School of Medicine, University of Calgary, Calgary Alberta, Canada

Search for other papers by Parthiv Amin MASc in
Google Scholar
PubMed Close
,
Sana Ghaznavi Arnie Charbonneau Cancer Institute, Department of Medicine, Section of Endocrinology, University of Calgary, Calgary, Alberta, Canada

Search for other papers by Sana Ghaznavi in
Google Scholar
PubMed Close
,
Debbie Lamb Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Alberta, Canada

Search for other papers by Debbie Lamb in
Google Scholar
PubMed Close
,
John McIntyre Precision Oncology Hub Laboratory, Tom Baker Cancer Centre, Calgary, Alberta, Canada

Search for other papers by John McIntyre in
Google Scholar
PubMed Close
,
Markus Eszlinger Department of Oncology, Cumming School of Medicine, and Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada

Search for other papers by Markus Eszlinger in
Google Scholar
PubMed Close
, and
Ralf Paschke Departments of Medicine, Section of Endocrinology, Oncology, Pathology and Laboratory Medicine, Biochemistry and Molecular Biology and Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada

Search for other papers by Ralf Paschke in
Google Scholar
PubMed Close

). Recently, this strategy was extended to rarer oncogenic fusion genes like RET and NTRK1/2/3 rearrangements using the RET inhibitor selpercatinib and the NTRK inhibitor larotrectinib ( 6 , 8 , 9 ). The first instance of RAI uptake restoration leading

Article Type:
Research Article
Collections:
Thyroid cancer - basic and translational
DOI:
https://doi.org/10.1530/ETJ-23-0227
Volume/Issue:
Volume 13: Issue 3
Open access
Markus Eszlinger Departments of Oncology, Pathology and Laboratory Medicine, Biochemistry and Molecular Biology, and Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Heritage Medical Research Building, Calgary, Alberta, Canada
Institute of Pathology, University Hospital Halle (Saale), Halle (Saale), Germany

Search for other papers by Markus Eszlinger in
Google Scholar
PubMed Close
,
Paul Stewardson Department of Medical Science and Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Calgary, Canada

Search for other papers by Paul Stewardson in
Google Scholar
PubMed Close
,
John B McIntyre Precision Oncology Hub Laboratory, Alberta Health Services, Tom Baker Cancer Centre, Calgary, Alberta, Canada

Search for other papers by John B McIntyre in
Google Scholar
PubMed Close
,
Adrian Box Department of Pathology and Laboratory Medicine, Cumming School of Medicine, University of Calgary, Calgary, Canada

Search for other papers by Adrian Box in
Google Scholar
PubMed Close
,
Moosa Khalil Department of Pathology and Laboratory Medicine, Cumming School of Medicine, University of Calgary, Calgary, Canada

Search for other papers by Moosa Khalil in
Google Scholar
PubMed Close
,
Martin Hyrcza Department of Pathology and Laboratory Medicine, Cumming School of Medicine, University of Calgary, Calgary, Canada

Search for other papers by Martin Hyrcza in
Google Scholar
PubMed Close
,
Konstantin Koro Department of Pathology and Laboratory Medicine, Cumming School of Medicine, University of Calgary, Calgary, Canada

Search for other papers by Konstantin Koro in
Google Scholar
PubMed Close
,
Dean Ruether Section of Medical Oncology, Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, Canada

Search for other papers by Dean Ruether in
Google Scholar
PubMed Close
,
Jiahui Wu Department of Medical Science and Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Calgary, Canada

Search for other papers by Jiahui Wu in
Google Scholar
PubMed Close
, and
Ralf Paschke Departments of Medicine, Oncology, Pathology and Laboratory Medicine, Biochemistry and Molecular Biology, and Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Heritage Medical Research Building, Calgary, Alberta, Canada

Search for other papers by Ralf Paschke in
Google Scholar
PubMed Close

Introduction The neurotrophic tyrosine kinase receptor (NTRK) inhibitors, larotrectinib and entrectinib, were approved by the United States Food & Drug Administration (FDA) for the treatment of NTRK fusion-positive solid tumors that are

Article Type:
Research Article
Collections:
Thyroid cancer - basic and translational
DOI:
https://doi.org/10.1530/ETJ-21-0061
Volume/Issue:
Volume 11: Issue 1
Open access
Inês Damásio Endocrinology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal

Search for other papers by Inês Damásio in
Google Scholar
PubMed Close
,
Joana Simões-Pereira Endocrinology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal

Search for other papers by Joana Simões-Pereira in
Google Scholar
PubMed Close
,
Sara Donato Endocrinology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
Nova Medical School, Lisbon, Portugal

Search for other papers by Sara Donato in
Google Scholar
PubMed Close
,
Mariana Horta Radiology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon Portugal

Search for other papers by Mariana Horta in
Google Scholar
PubMed Close
,
Branca Maria Cavaco Molecular Pathobiology Research Unit (UIPM), Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal

Search for other papers by Branca Maria Cavaco in
Google Scholar
PubMed Close
,
Miguel Rito Pathology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal

Search for other papers by Miguel Rito in
Google Scholar
PubMed Close
,
Pedro Gomes Head and Neck Surgery Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal

Search for other papers by Pedro Gomes in
Google Scholar
PubMed Close
, and
Valeriano Leite Endocrinology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
Nova Medical School, Lisbon, Portugal

Search for other papers by Valeriano Leite in
Google Scholar
PubMed Close

, approved by Food and Drug Administration (FDA) and by the European Medicines Agency (EMA), targeting NTRK fusions – larotrectinib and entrectinib – which represent two of the few ‘tumor-agnostic’ treatments available. Larotrectinib, a selective pan

Article Type:
Case Report
Collections:
Thyroid cancer - clinical
DOI:
https://doi.org/10.1530/ETJ-22-0179
Volume/Issue:
Volume 12: Issue 1
Open access
Pepijn van Houten Department of Internal Medicine, Division of Endocrinology, Radboud University Medical Center, Nijmegen, the Netherlands

Search for other papers by Pepijn van Houten in
Google Scholar
PubMed Close
,
James Nagarajah Roentgeninstitut Duesseldorf, Duesseldorf, Germany
Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, the Netherlands

Search for other papers by James Nagarajah in
Google Scholar
PubMed Close
,
Janneke E W Walraven Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands

Search for other papers by Janneke E W Walraven in
Google Scholar
PubMed Close
,
Martin Jaeger Department of Internal Medicine, Division of Endocrinology, Radboud University Medical Center, Nijmegen, the Netherlands

Search for other papers by Martin Jaeger in
Google Scholar
PubMed Close
,
Adriana C H van Engen-van Grunsven Department of Pathology, Radboud University Medical Center, Nijmegen, the Netherlands

Search for other papers by Adriana C H van Engen-van Grunsven in
Google Scholar
PubMed Close
,
Johannes W Smit Department of Internal Medicine, Division of Endocrinology, Radboud University Medical Center, Nijmegen, the Netherlands

Search for other papers by Johannes W Smit in
Google Scholar
PubMed Close
, and
Romana T Netea-Maier Department of Internal Medicine, Division of Endocrinology, Radboud University Medical Center, Nijmegen, the Netherlands
Research Center for Functional Genomics, Biomedicine and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania

Search for other papers by Romana T Netea-Maier in
Google Scholar
PubMed Close

inhibitors dabrafenib and vemurafenib, MEK inhibitors trametinib and selumetinib, RET inhibitor selpercatinib, and TRK inhibitor larotrectinib) regarding the enhancement of RAI uptake in RAI-refractory NMTC patients. Although these results are promising

Article Type:
Research Article
Collections:
Thyroid cancer - clinical
DOI:
https://doi.org/10.1530/ETJ-24-0153
Volume/Issue:
Volume 13: Issue 4
Open access
Jihwan Yoo Department of Neurosurgery, Brain Tumor Center, Gangnam Severance Hospital, Seoul, Republic of Korea
College of Medicine, Yonsei University, Seoul, Republic of Korea

Search for other papers by Jihwan Yoo in
Google Scholar
PubMed Close
,
Hee Jun Kim Department of Surgery, CHA Ilsan Medical Center, Cha University School of Medicine, Goyang-si, Republic of Korea

Search for other papers by Hee Jun Kim in
Google Scholar
PubMed Close
,
Seok Mo Kim Department of Surgery, Thyroid Cancer Center, Gangnam Severance Hospital, Institute of Refractory Thyroid Cancer, Yonsei University College of Medicine, Seoul, Republic of Korea

Search for other papers by Seok Mo Kim in
Google Scholar
PubMed Close
, and
Hun Ho Park Department of Neurosurgery, Brain Tumor Center, Gangnam Severance Hospital, Seoul, Republic of Korea

Search for other papers by Hun Ho Park in
Google Scholar
PubMed Close

reported to have neurotrophic tropomyosin receptor kinase (NTRK) fusions ( 27 ). In a pooled analysis of 1/2 clinical trials, 79% of 24 patients with DTC bearing an NTRK fusion who received larotrectinib demonstrated an objective response ( 28 ). Pitoia

Article Type:
Research Article
Collections:
Thyroid cancer - clinical
DOI:
https://doi.org/10.1530/ETJ-22-0087
Volume/Issue:
Volume 11: Issue 5
Open access
Janice Ser Huey Tan Division of Radiation Oncology, National Cancer Centre Singapore, Hospital Boulevard, Singapore

Search for other papers by Janice Ser Huey Tan in
Google Scholar
PubMed Close
,
Timothy Kwang Yong Tay Department of Pathology, Singapore General Hospital, Singapore

Search for other papers by Timothy Kwang Yong Tay in
Google Scholar
PubMed Close
,
Enya Hui Wen Ong Division of Radiation Oncology, National Cancer Centre Singapore, Hospital Boulevard, Singapore

Search for other papers by Enya Hui Wen Ong in
Google Scholar
PubMed Close
,
Michael Fehlings ImmunoScape, 1 Scotts Road #24-10, Singapore

Search for other papers by Michael Fehlings in
Google Scholar
PubMed Close
,
Daniel Shao-Weng Tan Division of Medical Oncology, National Cancer Centre Singapore, Hospital Boulevard, Singapore

Search for other papers by Daniel Shao-Weng Tan in
Google Scholar
PubMed Close
,
Nadiah Binte Sukma Department of Pathology, Singapore General Hospital, Singapore

Search for other papers by Nadiah Binte Sukma in
Google Scholar
PubMed Close
,
Eileen Xueqin Chen Department of Pathology, Singapore General Hospital, Singapore

Search for other papers by Eileen Xueqin Chen in
Google Scholar
PubMed Close
,
Jen-Hwei Sng Department of Pathology, Singapore General Hospital, Singapore

Search for other papers by Jen-Hwei Sng in
Google Scholar
PubMed Close
,
Connie Siew Poh Yip Division of Radiation Oncology, National Cancer Centre Singapore, Hospital Boulevard, Singapore

Search for other papers by Connie Siew Poh Yip in
Google Scholar
PubMed Close
,
Kok Hing Lim Department of Pathology, Singapore General Hospital, Singapore

Search for other papers by Kok Hing Lim in
Google Scholar
PubMed Close
,
Darren Wan-Teck Lim Division of Medical Oncology, National Cancer Centre Singapore, Hospital Boulevard, Singapore

Search for other papers by Darren Wan-Teck Lim in
Google Scholar
PubMed Close
,
Narayanan Gopalakrishna Iyer Division of Surgical Oncology, National Cancer Centre Singapore, Hospital Boulevard, Singapore

Search for other papers by Narayanan Gopalakrishna Iyer in
Google Scholar
PubMed Close
,
Jacqueline Siok Gek Hwang Department of Pathology, Singapore General Hospital, Singapore

Search for other papers by Jacqueline Siok Gek Hwang in
Google Scholar
PubMed Close
,
Melvin Lee Kiang Chua Division of Radiation Oncology, National Cancer Centre Singapore, Hospital Boulevard, Singapore

Search for other papers by Melvin Lee Kiang Chua in
Google Scholar
PubMed Close
, and
Mei-Kim Ang Division of Medical Oncology, National Cancer Centre Singapore, Hospital Boulevard, Singapore

Search for other papers by Mei-Kim Ang in
Google Scholar
PubMed Close

-free survival (PFS) and OS rates of 79% and 80%, respectively ( 7 ). NTRK fusions have been also detected in 5–25% of all thyroid cancers, and in a recent phase 1–2 basket trial of an NTRK inhibitor – larotrectinib, the ORR amongst 28 patients with thyroid

Article Type:
Research Article
Collections:
Thyroid cancer - clinical
DOI:
https://doi.org/10.1530/ETJ-23-0144
Volume/Issue:
Volume 13: Issue 1
Open access
Benjamin Chevalier Department of Endocrinology, Diabetology and Metabolism, Lille University Hospital, Lille, France
University of Lille, Lille, France

Search for other papers by Benjamin Chevalier in
Google Scholar
PubMed Close
,
Oriane Karleskind Department of Pathology, Lille University Hospital, Lille, France

Search for other papers by Oriane Karleskind in
Google Scholar
PubMed Close
,
Arnaud Jannin Department of Endocrinology, Diabetology and Metabolism, Lille University Hospital, Lille, France
University of Lille, Lille, France

Search for other papers by Arnaud Jannin in
Google Scholar
PubMed Close
,
Olivier Farchi Department of Biochemistry and Molecular Biology, Hormonology Metabolism Nutrition Oncology, Lille University Hospital, Lille, France

Search for other papers by Olivier Farchi in
Google Scholar
PubMed Close
,
Catherine Vermaut Department of Biochemistry and Molecular Biology, Hormonology Metabolism Nutrition Oncology, Lille University Hospital, Lille, France

Search for other papers by Catherine Vermaut in
Google Scholar
PubMed Close
,
Alexandre Escande Academic Department of Radiation Oncology, Oscar Lambret Comprehensive Cancer Center, Lille, France
CRIStAL UMR CNRS 9189, University of Lille, Villeneuve-d’Ascq, France

Search for other papers by Alexandre Escande in
Google Scholar
PubMed Close
,
Clio Baillet Department of Nuclear Medicine, Lille University Hospital, Lille, France

Search for other papers by Clio Baillet in
Google Scholar
PubMed Close
,
Stéphanie Espiard Department of Endocrinology, Diabetology and Metabolism, Lille University Hospital, Lille, France
University of Lille, Lille, France
Institut National de la Santé et de la Recherche Médicale (INSERM), European Genomic Institute for Diabetes (EGID), CHU Lille, Lille, France

Search for other papers by Stéphanie Espiard in
Google Scholar
PubMed Close
,
Marie-Christine Vantyghem Department of Endocrinology, Diabetology and Metabolism, Lille University Hospital, Lille, France
University of Lille, Lille, France
Institut National de la Santé et de la Recherche Médicale (INSERM), European Genomic Institute for Diabetes (EGID), CHU Lille, Lille, France

Search for other papers by Marie-Christine Vantyghem in
Google Scholar
PubMed Close
,
Bruno Carnaille University of Lille, Lille, France

Search for other papers by Bruno Carnaille in
Google Scholar
PubMed Close
,
Emmanuelle Leteurtre University of Lille, Lille, France
Department of Pathology, Lille University Hospital, Lille, France
University of Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, Lille, France

Search for other papers by Emmanuelle Leteurtre in
Google Scholar
PubMed Close
, and
Christine Do Cao Department of Endocrinology, Diabetology and Metabolism, Lille University Hospital, Lille, France

Search for other papers by Christine Do Cao in
Google Scholar
PubMed Close

, ceritinib, selpercatinib, pralsetinib, larotrectinib) ( 45 , 46 , 47 , 48 ). CDKN2A / B deletions/mutations could also potentially benefit from cell cycle inhibitors ( 49 ). We hypothesize from these two patients that MSI increases chemoradiotherapy

Article Type:
Case Report
Collections:
Thyroid cancer - clinical
DOI:
https://doi.org/10.1530/ETJ-22-0111
Volume/Issue:
Volume 12: Issue 1
Open access
Jaume Capdevila Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), IOB Quiron-Teknon, Barcelona, Spain

Search for other papers by Jaume Capdevila in
Google Scholar
PubMed Close
,
Desiree’ Deandreis Department of Medical Sciences, Nuclear Medicine Unit, University of Turin, AOU Città della Salute e della Scienza, Turin, Italy

Search for other papers by Desiree’ Deandreis in
Google Scholar
PubMed Close
,
Cosimo Durante Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy

Search for other papers by Cosimo Durante in
Google Scholar
PubMed Close
,
Sophie Leboulleux Service of Endocrinology, Diabetology, University Hospital Geneve, Geneve, Switzerland

Search for other papers by Sophie Leboulleux in
Google Scholar
PubMed Close
,
Markus Luster Department of Nuclear Medicine, University Hospital Marburg, Marburg, Germany

Search for other papers by Markus Luster in
Google Scholar
PubMed Close
,
Romana Netea-Maier Department of Internal Medicine, Division of Endocrinology, Radboud University Medical Center, Nijmegen, The Netherlands

Search for other papers by Romana Netea-Maier in
Google Scholar
PubMed Close
,
Kate Newbold Royal Marsden Hospital, London, United Kingdom

Search for other papers by Kate Newbold in
Google Scholar
PubMed Close
,
Susanne Singer Institute of Medical Biostatistics Epidemiology and Informatics (IMBEI), University Medical Center of Johannes Gutenberg University, Mainz, Germany

Search for other papers by Susanne Singer in
Google Scholar
PubMed Close
,
Gerasimos P Sykiotis Service of Endocrinology, Diabetology and Metabolism, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland

Search for other papers by Gerasimos P Sykiotis in
Google Scholar
PubMed Close
,
Beate Bartes Association “Vivre sans Thyroïde”, Léguevin, France

Search for other papers by Beate Bartes in
Google Scholar
PubMed Close
,
Kate Farnell Butterfly Thyroid Cancer Trust, Rowlands Gill, Tyne & Wear, UK

Search for other papers by Kate Farnell in
Google Scholar
PubMed Close
, and
Laura Deborah Locati Medical Oncology Unit, IRCCS ICS Maugeri, Pavia, Italy
Department of Internal Medicine and Therapeutics, University of Pavia, Italy

Search for other papers by Laura Deborah Locati in
Google Scholar
PubMed Close

previously been treated with lenvatinib and/or sorafenib in adult and adolescent (≥12 years) patients with RET-mutant MTC. Tailored agents such as entrectinib and larotrectinib obtained an agnostic approval in the presence of an NTRK rearrangement, while

Article Type:
Research Article
Collections:
Thyroid cancer - clinical
DOI:
https://doi.org/10.1530/ETJ-23-0068
Volume/Issue:
Volume 12: Issue 5
Open access
Zoe A. Efstathiadou Department of Endocrinology, “Hippokration” General Hospital of Thessaloniki, Thessaloniki, Greece

Search for other papers by Zoe A. Efstathiadou in
Google Scholar
PubMed Close
,
Charalambos Tsentidis Department of Endocrinology, General Hospital of Nikaia “Agios Panteleimon”, Piraeus, Greece

Search for other papers by Charalambos Tsentidis in
Google Scholar
PubMed Close
,
Alexandra Bargiota Department of Endocrinology, University of Thessaly, Larisa, Greece

Search for other papers by Alexandra Bargiota in
Google Scholar
PubMed Close
,
Vasiliki Daraki Department of Endocrinology, University Hospital of Crete, Heraklion, Greece

Search for other papers by Vasiliki Daraki in
Google Scholar
PubMed Close
,
Kalliopi Kotsa Department of Endocrinology, “Ahepa” Hospital, Aristotle University, Thessaloniki, Greece

Search for other papers by Kalliopi Kotsa in
Google Scholar
PubMed Close
,
Georgia Ntali Department of Endocrinology, Diabetes and Metabolism, “Evangelismos” Hospital Athens, Athens, Greece

Search for other papers by Georgia Ntali in
Google Scholar
PubMed Close
,
Labrini Papanastasiou Department of Endocrinology and Diabetes Center, Athens General Hospital “G. Gennimatas”, Athens, Greece

Search for other papers by Labrini Papanastasiou in
Google Scholar
PubMed Close
,
Stelios Tigas Department of Endocrinology, University of Ioannina, Ioannina, Greece

Search for other papers by Stelios Tigas in
Google Scholar
PubMed Close
,
Konstantinos Toulis Department of Endocrinology, 424 Military Hospital, Thessaloniki, Greece

Search for other papers by Konstantinos Toulis in
Google Scholar
PubMed Close
,
Kalliopi Pazaitou-Panayiotou Division of Endocrinology, Endocrine Oncology, Interbalkan Medical Center, Thessaloniki, Greece

Search for other papers by Kalliopi Pazaitou-Panayiotou in
Google Scholar
PubMed Close
, and
Maria Alevizaki Endocrine Unit, Department of Medical Therapeutics, School of Medicine, Kapodistrian University of Athens, Athens, Greece

Search for other papers by Maria Alevizaki in
Google Scholar
PubMed Close

motesanib OR XL184 OR avastin OR bevacizumab OR alvocidib OR orantinib OR selumetinib OR semaxinib OR vatalanib OR AP24534 OR anlotinib OR nintedanib OR larotrectinib OR bortezomib OR sulfatinib OR tipifarnib OR LOXO-101 OR LOXO-292). Selection of

Article Type:
Meta Analysis
DOI:
https://doi.org/10.1159/000509457
Volume/Issue:
Volume 10: Issue 2
Free access
Junyu Tong Department of Nuclear Medicine, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, People’s Republic of China
Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, People’s Republic of China

Search for other papers by Junyu Tong in
Google Scholar
PubMed Close
,
Maomei Ruan Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, People’s Republic of China
Department of Nuclear Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, People’s Republic of China

Search for other papers by Maomei Ruan in
Google Scholar
PubMed Close
,
Yuchen Jin Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, People’s Republic of China

Search for other papers by Yuchen Jin in
Google Scholar
PubMed Close
,
Hao Fu Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, People’s Republic of China

Search for other papers by Hao Fu in
Google Scholar
PubMed Close
,
Lin Cheng Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, People’s Republic of China

Search for other papers by Lin Cheng in
Google Scholar
PubMed Close
,
Qiong Luo Department of Nuclear Medicine, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, People’s Republic of China

Search for other papers by Qiong Luo in
Google Scholar
PubMed Close
,
Zhiyan Liu Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, People’s Republic of China
Department of Pathology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, People’s Republic of China

Search for other papers by Zhiyan Liu in
Google Scholar
PubMed Close
,
Zhongwei Lv Department of Nuclear Medicine, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, People’s Republic of China

Search for other papers by Zhongwei Lv in
Google Scholar
PubMed Close
, and
Libo Chen Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, People’s Republic of China

Search for other papers by Libo Chen in
Google Scholar
PubMed Close

. New England Journal of Medicine 2013 368 623 – 632 . ( https://doi.org/10.1056/NEJMoa1209288 ) 85 Groussin L Clerc J Huillard O . Larotrectinib-enhanced radioactive iodine uptake in advanced thyroid cancer . New England Journal of Medicine

Article Type:
Review Article
Collections:
Thyroid cancer - clinical
DOI:
https://doi.org/10.1530/ETJ-22-0021
Volume/Issue:
Volume 11: Issue 2
Open access